MA55958A - Agents antifongiques, tels que l'ibrexafungerp pour la décolonisation de candida auris - Google Patents

Agents antifongiques, tels que l'ibrexafungerp pour la décolonisation de candida auris

Info

Publication number
MA55958A
MA55958A MA055958A MA55958A MA55958A MA 55958 A MA55958 A MA 55958A MA 055958 A MA055958 A MA 055958A MA 55958 A MA55958 A MA 55958A MA 55958 A MA55958 A MA 55958A
Authority
MA
Morocco
Prior art keywords
ibrexafungerp
decolonization
antifungal agents
candida auris
auris
Prior art date
Application number
MA055958A
Other languages
English (en)
French (fr)
Inventor
Gonzalez David A Angulo
Stephen Andrew Barat
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of MA55958A publication Critical patent/MA55958A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
MA055958A 2019-05-16 2020-05-12 Agents antifongiques, tels que l'ibrexafungerp pour la décolonisation de candida auris MA55958A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962849019P 2019-05-16 2019-05-16

Publications (1)

Publication Number Publication Date
MA55958A true MA55958A (fr) 2022-03-23

Family

ID=70861571

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055958A MA55958A (fr) 2019-05-16 2020-05-12 Agents antifongiques, tels que l'ibrexafungerp pour la décolonisation de candida auris

Country Status (14)

Country Link
US (1) US20220211684A1 (https=)
EP (1) EP3968986A1 (https=)
JP (2) JP7770191B2 (https=)
KR (1) KR20220009416A (https=)
CN (1) CN113905733A (https=)
AU (1) AU2020276595B2 (https=)
BR (1) BR112021022876A2 (https=)
CA (1) CA3140637A1 (https=)
EA (1) EA202193146A1 (https=)
IL (1) IL288165B1 (https=)
MA (1) MA55958A (https=)
MX (1) MX2021013899A (https=)
TW (2) TWI881977B (https=)
WO (1) WO2020232037A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250006380A (ko) 2023-07-03 2025-01-13 연세대학교 산학협력단 칸디다 아우리스에 대한 항진균제 스크리닝 방법 및 항진균용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
JP5245057B2 (ja) 2006-04-03 2013-07-24 メルク・シャープ・アンド・ドーム・コーポレーション 抗真菌剤
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
KR101686075B1 (ko) * 2008-08-12 2016-12-13 싸이넥시스, 인크. 항균제
MA43825A (fr) * 2016-03-16 2021-04-07 Cidara Therapeutics Inc Schémas posologiques pour le traitement d'infections fongiques
MA49889A (fr) * 2017-04-10 2020-06-24 Scynexis Inc Agents antifongiques utilisés en association
AU2018269892A1 (en) * 2017-05-17 2019-11-28 T2 Biosystems, Inc. NMR methods and systems for the rapid detection of Candida species
KR102807716B1 (ko) * 2017-08-04 2025-05-13 싸이넥시스, 인크. 산성 pH에서 증진된 활성을 갖는 항진균제
US20220117948A1 (en) * 2019-01-30 2022-04-21 Scynexis, Inc. Triterpenoid antifungals for the treatment of fungal osteo-articular infections

Also Published As

Publication number Publication date
CN113905733A (zh) 2022-01-07
TW202110441A (zh) 2021-03-16
EA202193146A1 (ru) 2022-02-11
US20220211684A1 (en) 2022-07-07
CA3140637A1 (en) 2020-11-19
MX2021013899A (es) 2022-02-10
IL288165B1 (en) 2026-01-01
KR20220009416A (ko) 2022-01-24
EP3968986A1 (en) 2022-03-23
AU2020276595A1 (en) 2021-12-09
AU2020276595B2 (en) 2025-12-04
TWI881977B (zh) 2025-05-01
WO2020232037A1 (en) 2020-11-19
JP2025118765A (ja) 2025-08-13
BR112021022876A2 (pt) 2022-04-12
JP2022532734A (ja) 2022-07-19
TW202602460A (zh) 2026-01-16
JP7770191B2 (ja) 2025-11-14
IL288165A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
EP3924799A4 (en) GEO REFERENCE POINTS FOR UAV NAVIGATION
EP3833739A4 (en) AKKOMANSIA MUCINIPHILA
EP3465554A4 (en) PERSONALIZED CHATBOTS FOR PRISONERS
EP3982105A4 (en) BALANCE ADJUSTMENT PROCEDURE FOR LIFT
CL2017002883A1 (es) Derivados de 2-(feniloxi o feniltio)pirimidina como herbicidas
EP4013496A4 (en) THROMBOSOMES AS AN AGENT FOR REMOVING THE THROMBOCYTE AGGREGATION-INHIBITING EFFECT
EP4085144A4 (en) COMPOSITIONS FOR THE TREATMENT OF FRIEDREICH AAXIA
EP3884053A4 (en) COMPOUNDS AND METHODS FOR REDUCING PRION EXPRESSION
EP3853365A4 (en) MODULATORS OF PNPLA3 EXPRESSION
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MA47469A (fr) Dérivés 2-(3-(1h-benzo[d]imidazol-1-yl)propyl)pipéridin-3-ol et composés similaires en tant q'inhibiteurs prs pour le traitement du cancer
EP3934466A4 (en) UNDERWEAR FOR MEN
EP3823978A4 (en) Fcrn antibody compositions
EP3950905A4 (en) LUBRICATION OIL COMPOSITION
MA52154A (fr) Composition pharmaceutique pour l'anémie
EP3817750A4 (en) CANNABIDIOL COMBINATION COMPOSITIONS
EP3746058C0 (en) COMPOSITIONS AND METHODS TO INCREASE THE BIOAVAILABILITY OF 5-HYDROXYTRYPTOPHAN
EP3888715A4 (en) COMPOSITION FOR TRANSPLANTATION OF AN ORGANOID
EP4058062A4 (en) Compositions and methods for immunotherapy
EP4083173A4 (en) LUBRICATING OIL COMPOSITION
MA41809B1 (fr) Biotine pour le traitement de la sclérose latérale amyotrophique
EP3972621A4 (en) CANNABINOID COMPOSITIONS FOR PAIN MANAGEMENT
MA55958A (fr) Agents antifongiques, tels que l'ibrexafungerp pour la décolonisation de candida auris
MA54283A (fr) Pyrazoles utilisés utilisés comme modulateurs de l'hémoglobine
EP3946380A4 (en) COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY